(UroToday.com) In this presentation, Dr. Thomas Powles presented results from the Phase 2 NORSE study of erdafitinib or erdafitinib plus cetrelimab in patients with metastatic or locally advanced urothelial carcinoma (UC) and fibroblast growth factor receptor (FGFR) alterations. These preliminary results discussed by Dr. Thomas Powles focused on overall response rate (ORR) and safety data.